Healthcare & Life Sciences

Healthcare and life sciences span biopharma, medical device, diagnostics, and healthcare services companies at every stage from clinical development through commercial scale. Demand is supported by an aging global population, patent expirations that push large manufacturers toward licensing and acquisition, and the growing use of artificial intelligence in drug discovery and diagnostics. Reimbursement policy and regulatory review timelines shape commercial outcomes as much as the underlying science. Capital markets activity moves in cycles with investor risk appetite, with stronger periods often tied to clinical breakthroughs in areas such as oncology, rare disease, and gene therapy. The financing pattern is distinctive: development-stage companies raise capital repeatedly between milestones, often years before revenue, so continuity of market access matters as much as the terms of any single transaction. A.G.P. supports healthcare and life sciences companies across equity and debt financing, M&A advisory, and research coverage.